Trials / Completed
CompletedNCT05064839
Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 553 (actual)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
Heart failure with preserved ejection and hypertrophic cardiomyopathy are common diseases and often associated with transthyretin cardiac amyloidosis (TTR-CM), especially in elderly people. Nevertheless, research of TTR-CM is recommended in patients with ventricular hypertrophy without other cause such as valvular disease or hypertension. Therefore, the exact prevalence of TTR-CM remains unknown. We aim to determine the prevalence of TTR-CM in patients with ventricular hypertrophy and aged ≥ 60 years old, hospitalized in our cardiology department (CHU de Poitiers) by performing bone scintigraphy and research of AL amyloidosis.
Detailed description
Not Provided
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Bony scintigraphy | Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle |
Timeline
- Start date
- 2021-10-06
- Primary completion
- 2023-08-18
- Completion
- 2023-08-18
- First posted
- 2021-10-01
- Last updated
- 2023-09-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05064839. Inclusion in this directory is not an endorsement.